Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III trial of AGA111 in degenerative disc disease patients undergoing lumbar interbody fusion
CTR20233338Phase 3Terminated
- Sponsor
- Angitia Biopharmaceuticals
- Start
- Dec 2023
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 3 trial of AGA111 in degenerative disc disease (DDD), sponsored by Angitia Biopharmaceuticals. Started Dec 2023; status: terminated.
02
Drugs
AGA111
03
Conditions
degenerative disc disease (DDD)
Beyond the preview
Go deeper on CTR20233338.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20233338.